Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2017.0064
• Publication Date: 2017-05-26T15:20:45Z
• Authors: Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Patricia Aoun; Celeste M. Bello; Cecil M. Benitez; Karl Bernat; Philip J. Bierman; Kristie A. Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I. Gordon; Francisco J. Hern...; Ephraim P. Hochberg; Jiayi Huang; Patrick B. Johnston; Mark S. Kaminski; Vaishalee P. Kenkre; Nadia Khan; David G. Maloney; Peter M. Mauch; Monika Metzger; Joseph O. Moore; David Morgan; Craig H. Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Mitchell Smith; Jane N. Winter; Joachim Yahalom; Jennifer Burns; Ndiya Ogba; Hema Sundar
• Keywords: Classical Hodgkin lymphoma; Clinical Practice

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on management classical HL. Current HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging PET/CT to assess response using Deauville criteria (5-point scale). The introduction less toxic and more effective regimens has significantly advanced cure rates. However, long-term follow-up after completion is essential determine potential effects.